NUDCD3

Across TCGA pan-cancer cohorts, NUDCD3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NUDCD3 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher NUDCD3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NUDCD3 expression acts as an unfavorable survival marker.

SKCM, SARC, and UCS are the cancer types where NUDCD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	0.087	0.647	.013	7	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NUDCD3–SKCM (DFS)

Open the SKCM breakdown →